Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q Summary
Allogene Therapeutics reported no revenue and a widened net loss of $50.37M in Q3 2026, driven by increased R&D spending. EPS was ($0.15). The company advanced product candidates and expects cash runway into Q1 2029. Candidate tickers: ALLO.
How this was made
The 30-second read
Why it matters
The earnings miss underscores cash burn concerns, likely prompting short‑term price declines while investors await trial readouts.
Market read
Primary earnings disclosure for a listed biotech; new loss figures and zero revenue provide fresh trading signals.
What to watch
Potential upcoming data from ALLO‑329 and ALLO‑316 trials could offset short‑term earnings weakness.
Background
Allogene Therapeutics is a clinical‑stage biotech developing allogeneic CAR‑T cell therapies. The Q3 2026 filing shows no collaboration revenue and increased R&D spend as multiple trials progress.
Ticker impact
Allogene Therapeutics filed its 10‑Q reporting Q3 2026 results with zero collaboration revenue and a widened net loss of $50.37 M.
likely downside as investors price in higher loss and no revenue
The company posted a larger net loss than a year ago and no revenue, which typically triggers sell pressure in biotech stocks.
Market effects
Highlights continued cash burn in early‑stage cell‑therapy firms, may affect sector sentiment.
U.S. biotech investors may reassess exposure to cash‑intensive pipelines.
Limited; primarily relevant to U.S. biotech and specialty pharma investors.
Counterpoint
If the cash runway to 2029 is sufficient, the loss may be viewed as a necessary investment for future breakthroughs.
Key entities
- companyAllogene Therapeutics, Inc.
Biotech firm reporting Q3 2026 results.
